Contact this trialFirst, we need to learn more about you.
CAR T-cell Therapy
bb2121 for Multiple Myeloma
Recruiting2 awardsPhase 1
Hackensack, New Jersey
This trial is for a new cancer treatment for patients with multiple myeloma who have received 3 cycles of standard induction therapy. The treatment involves leukapheresis to collect autologous mononuclear cells, which are then manufactured into the drug product bb2121. Subjects receive bb2121 infusion after fourth cycle of induction therapy and lymphodepleting therapy. Maintenance therapy is recommended for all subjects who have received bb2121 infusion.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.